DURECT (NASDAQ:DRRX) is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for chronic diseases and acute conditions. Leveraging proprietary drug delivery platforms, the company is advancing a pipeline of small molecule and injectable products aimed at addressing pain management, liver disease and other areas of unmet medical need. DURECT’s research emphasizes novel mechanisms of action as well as extended‐release formulations to improve patient convenience and treatment outcomes.
The company’s two principal platforms, ORADUR® and SABER®, enable customized release profiles for both oral and injectable therapies. Through these technologies, DURECT is developing POSIDUR®, an extended‐release meloxicam injection for post‐operative pain, which has been licensed to international partners for regulatory filing in key markets. In addition, DURECT’s lead internally developed compound, DUR-928, is a small molecule in clinical evaluation for acute organ injuries and chronic liver diseases such as alcoholic hepatitis and nonalcoholic steatohepatitis (NASH).
Since its founding in 1998 and its subsequent initial public offering in 2004, DURECT has established collaborative relationships with global pharmaceutical companies to advance product candidates across multiple geographies. Licensing partnerships include agreements with Grünenthal for ex-U.S. commercialization of POSIDUR® and with Luye Pharma in Greater China. These alliances support DURECT’s strategy of combining in-house innovation with partner expertise to accelerate clinical development and expand market reach.
Headquartered in Cupertino, California, DURECT is led by a management team with extensive experience in drug development and commercial operations. President and Chief Executive Officer James E. Brown oversees corporate strategy and pipeline progression, supported by senior executives in research, regulatory affairs and business development. With an emphasis on scientific rigor and strategic partnership, DURECT continues to drive its mission of delivering differentiated therapies for patients worldwide.
